Press Releases for PFE

Press Releases
Poll: Most in world favor work smoking ban
Flamel Technologies Announces Third Quarter 2009 Results; Additional New Projects; Cash Increases from $45.1 to $48.8 million
Trading Outlook for BioElectronics Corporation Issued by StockPreacher.com
InSite Vision Reports Third Quarter 2009 Financial Results
Paladin Reports Record Third Quarter 2009 Financial Results
BDNA Webinar Helps Businesses Prepare for and Survive a Software Audit
Celldex Therapeutics Reports Third Quarter and Nine Month 2009 Financial Results
PicksThatMove.Com Announces Investment Opinion on TPS, ML, KOG, GAP and PFE
MichBio Expo &Amp; Conference Exhibitors Profiled
Ligand to Acquire Metabasis for Cash and Contingent Value Rights
Mission Bay Capital Announces First Venture Fund
ArthroCare Names David Fitzgerald President and CEO
Cutting Edge Information Investigates Pfizer-Wyeth Merger, Studies Current M&Amp;A Drivers
Kansas City Business Journalist Announces American Innovation Tour
Pfizer Reports Third-Quarter 2009 Results
Health Discovery Corporation Announces Additional Issued Patents and Notices of Allowance to Its Intellectual Property Portfolio
Pashminadepot.Com, Inc. Appoints Clive D. Harbutt to Its Board of Directors
Former Pharmaceutical Executive to Join M\|C Communications to Lead Domestic Sales
pSivida Announces Last Patient in Phase III Iluvien® Trial Completes 2 Year Follow-Up Visit
InSite Vision to Hold Annual Meeting of Stockholders
Global Health Ventures Inc. (OTCBB: GHLV) Commences an Investment Road Show, Starting in Montreal, Quebec and Then Presenting in London, England
Celldex Therapeutics Announces Completed Acquisition of CuraGen Corporation
Celldex and CuraGen Stockholders Approve Acquisition of CuraGen Corporation
Best Practices to Speed-Up Pharmaceutical Analysis Processes From Johnson & Johnson, Pfizer, Genentech and Eli Lilly at Pharma IQ's Forum on Laboratory Informatics
Free Webinar "Optimizing Your Supply Chain Using Leaner Business Practices”Ensuring Greater Supplier Quality"
UPI NewsTrack Business
Abbott to buy Solvay division for $6.6B
Lawsuits allege industries cause illnesses
pSivida Corp. Reports Results for the Fourth Quarter and Fiscal Year Ended June 30, 2009
The Global Sourcing Forum + Expo Highlights Sourcing Tracks for G20 Companies
For Sixth Consecutive Year, Pfizer Earns Highest Score In Human Rights Campaign Foundation LGBT Ranking
Deltagen Reports 2009 Second Quarter Financial Results
pSivida CEO to Discuss New Technologies in Retinal Drug Delivery at 5th Annual Ophthalmic Drug Development and Delivery Summit
pSivida Corp Announces Q4 and Fiscal Year 2009 Financial Results Release Date and Conference Call Information
GENova Biotherapeutics (GVBP) SqueezeTrigger Price is $0.43. Approximately 57 Million Shares Shorted Since July 2009 According to Buyins.Net Research Report
Stock in Focus: Sunwin International Neutraceuticals -- September 16, 2009
Symyx Joins SAFE-BioPharma to Ensure Safe Security Standards for ELN Software; Pharmaceutical Industry Non-Profit Maintains Standards and Certification for Digital Signatures
Fitch: Credit Quality Stable for Global Pharma Sector With Increase of New Drug Approvals in 2Q'09
UPI NewsTrack Quirks in the News
Man banned from displaying Viagra rocket
ViewCast Selects Twofour Digital As Consulting Systems Integrator in Europe and India ; Partnership Will Optimize Visibility in High-Potential Markets
Scott Livingston Keynotes at NanoBusiness 2009 Conference, and Announces 2nd Annual Livingston Healthcare, Life Science, and Nanotechnology Investor Summit
pSivida to Webcast Presentation at Rodman & Renshaw Health Care Conference
Celldex Therapeutics Announces Appointment of Larry Ellberger As Chairman of the Board
New Leaf Venture Partners Leads $30 Million Financing in Neuronetics
Pfizer to pay record fine for Bextra fraud
Fusing Science and Society: Media Entrepreneur Adam Bly Launches National Biotechnology Week in London, Ontario
Ahead of the Bell: Sunwin International Neutraceuticals - August 19, 2009
Wyeth Announces Full Redemption of Floating Rate Convertible Senior Debentures Due 2024
Executives From IBM, A.T. Kearney, Pfizer, Google, Best Buy, Citigroup to Present at the Global Sourcing Forum + Expo
BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results
BDNA Hosts Free Webinar Focused on Ways to Cut IT Costs and Increase ROI With Green IT
Pharmerging Versus Mature Pharmaceutical Markets: Where Is Pharma Going? Where Is Pharma Growing? -- an Industrial Info News Alert
Ligand Terminates Long-Term Lease Obligation
Imaginatik Secures $2.6m Growth Funding
MetricStream Continues Strong Growth Trend in First Half of 2009
Molecular Insight Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial and Operational Results
President Clinton, Pfizer, and Mylan Announce New Agreements to Lower Prices of Medicines for Patients with Drug-Resistant HIV in Developing Countries
Novo Nordisk: Half-Yearly Report
Celldex Reports Second Quarter and Six Month 2009 Financial Results
West Announces Second Quarter 2009 Results ; - Adjusted Diluted EPS (1) of $0.58 -; - Revises Adjusted Diluted EPS(1) Estimate to Between $2.10 and $2.20 -; - Conference Call Scheduled for 9 A.M. Today -
Ligand Pharmaceuticals Announces Second Quarter Results
Fitch Rates New London, Connecticut's $17MM 2009 GOs 'AA-'; Outlook Stable
Pfizer, Kano State Reach Settlement Of Trovan Cases
ParagonReport.Com Complimentary Market Update on MSFT, TWX, PFE and DOW
Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease
Pfizer and Fudan University Announce Joint Graduate Program in Clinical Research
StockPreacher Issues Trading Outlook for Varian Inc.
Pfizer Announces Partnership With Shanghai Institutes For Biological Sciences For Drug Discovery Activities
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
NicOx First Half 2009 Financial Results: Naproxcinod Nearing Regulatory Submissions in US and Europe
RenaissanceRe Reports Net Income Available to RenaissanceRe Common Shareholders of $271.2 Million for the Second Quarter of 2009 or $4.32 Per Diluted Common Share
Pfizer sues over non-kosher ingredient
Philippines cuts drug prices 50 percent
StockPreacher.com Issues Trading Outlook for Onyx Pharmaceuticals Inc. (ONXX)
UPI NewsTrack Business
ParagonReport.Com Complimentary Market Update on MRK, BMY, PFE and GSK
Pfizer Reports Second-Quarter 2009 Results; Increases Full-Year 2009 Adjusted Diluted EPS(1) Guidance
InvestorSoup.com Issues Trading Outlook for Johnson & Johnson
Identifying Companies to Benefit from Bull or Bear Market Outlook
96-Week MERIT ES Analysis Shows Efficacy Of Pfizer’s HIV/AIDS Treatment Celsentri/Selzentry (Maraviroc) In Treatment-Naïve HIV Patients; Results Consistent With 48-Week Analysis
Wyeth Announces Stockholder Approval of Pfizer Merger at 2009 Annual Meeting
Pfizer Receives Approval From European Commission For Pending Acquisition Of Wyeth
Johnson Controls Announces Web-Based Greenhouse Gas Reporting System ; System Measures, Manages and Reports Organizations' Global Carbon Footprints
ParagonReport.Com Complimentary Analyst Opinion on BAC, GE, JPM and PFE
Wyeth Announces Results of the Company's Offer Relating to Holder Right to Surrender Convertible Debentures
PharmaTelevision Launches New Premium Content Service
Pfizer Announces New Phase 1 Data From Two Novel Compounds For Alzheimer’s Disease At ICAD Annual Meeting
Burrill Merchant Banking Advises Pfizer Inc. On Dermatology Portfolio Divestment
Bitam Partners With Business Impact to Provide End-to-End Business Intelligence Solutions
BDNA Presents at Morgan Stanley's 9th Annual CTO Summit
Pfizer To Appeal Canadian Federal Court Decision On Company's Norvasc® Patent
Pfizer To Appeal Canadian Federal Court Decision On Company’s Norvasc® Patent
ParagonReport.Com Complimentary Analyst Opinion on PFE and GSK
OneChicago Reports June Volume
Healthcare Hiring Insiders to Lobby
MorphoSys Secures Full-Term of Strategic Alliance
MorphoSys and the University of Melbourne File New Patent Applications in MOR103 Program
Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecules from Pfizer
FDA to require warnings for Chantix, Zyban